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Sir,
In the January 26, 2004 issue, Petrioli et al (2004) reported a
small phase II study of 41 patients with metastasic colorectal
cancer treated with UFT/leucovorin and oxaliplatin or UFT/
leucovorin and irinotecan alternatively. The overall response
(58.5%), median progression-free survival (8.8 months) and
median overall survival (17.3) months are comparable to those
of previous reported combinations including either oxaliplatin or
irinotecan (de Gramont et al, 2000; Douillard et al, 2000; Saltz et al,
2000), but with no grade 4 toxicity. Nevertheless, this study is
questionable by many aspects. The first point to discuss is the
inevitable selection bias illustrated by the favourable general status
and the wide predominance (93%) of patients with 1 or 2
metastatic sites. Many baseline characteristics have not been
precised such as albumin, lactate dehydrogenase, alkaline phos-
phatases, or carcinoembryonic antigen levels. Metastasectomy has
been performed in about 20% of cases despite very low-dose
intensities. This secondary surgery introduces a major confusing
factor since prolonged survival and probably cure rates of about
20% can be obtained (Elias et al, 1998). Above all, there is a major
recruitment bias since 85% of the patients have had been operated
for a primary tumour, favouring the early detection of metastases,
leading to the selection of patients with low tumour burden and,
consequently, to a potential advantage in terms of therapeutic
efficacy and tolerance. However, the dose intensities of irinotecan
and oxaliplatin are only 36 and 17mgm
 2 in this study vs 90 and
50mgm
 2, respectively, in the FOLFIRI and FOLFOX6 regimens
and up to 100 and 65mgm
 2 in the recent intensified FOLFIRI-3
(Mabro et al, 2003) and FOLFOX7 versions (Maindrault-Goebel
et al, 2001). UFT also is administered at a dose which is that
recommended for combination with a full dose of irinotecan
(Alonso et al, 2001; Mackay et al, 2003). Given the rarity of
diarrhoea under oxaliplatin, higher doses of UFT might be
combined with this agent (Kim et al, 2002).
In fact, the aim of the study may be discussed since efficacy
should be privileged in such selected patients potentially
candidates to secondary surgery. Possibly, more patients might
have benefited from this approach with heavier regimens, taking
into account progresses in surgery allowing the treatment of
patients with liver and lung metastases (Mineo et al, 2003). The
question of the selection of resistant clones by low doses also must
be addressed. The evaluation of response to either oxaliplatin or
irinotecan is extremely difficult with the alternated regimens.
Consequently, second-line chemotherapy should have been a
dilemma since the investigators had to use mitomycin. This study
contributes to demonstrate that, at present, the neoadjuvant
approach should be clearly distinguished from palliative che-
motherapy. There is also a need for rapid integration of biological
predictive factors of response (Etienne et al, 2002; Arango et al,
2003; Fallik et al, 2003; Mariadason et al, 2003).
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Sir,
We would like to thank Dr Alliot for his comments concerning
our study of metastatic colorectal cancer patients treated with
UFT/LVþL-HOP alternated with UFT/LVþCPT-11 (Petrioli et al,
2004).
In relation to the baseline characteristics of the enrolled
patients, it was pointed out in the Discussion that ‘the performance
status and the percentage of chemonaive patients suggested a
better than average group with regard to efficacy and toxicity’.
As far as metastatic sites are concerned, a selection bias is common
to small phase II studies. It is also worth pointing out that most
of the metastatic colorectal cancer patients enrolled in clinical
trials have p2 metastatic sites (as in our study population).
Furthermore, patients undergoing surgery for colorectal cancer are
unlikely to have metastatic sites other than the liver, lung and
peritoneum, and those having three or more metastatic sites are
unlikely to have a performance status that would allow their
enrolment in a chemotherapeutic protocol. Finally, phase II studies
do not usually report baseline CEA, albumin and LDH levels
because these have little prognostic value in the case of patients
with advanced disease (Douillard et al, 2000; Saltz et al, 2000;
Souglakos et al, 2002; Zeuli et al, 2003).
In relation to the low level of toxicity, it should be remembered
that this was also due to the advantage of oral chemotherapy: that
is, unlike boluses and continuous infusions, the treatment can be
discontinued when toxicity arises and before it worsens (Twelves
and Cassidy, 2002).
About 20% of our patients underwent postchemotherapy
surgery for residual metastases, thus confirming the efficacy of
the proposed chemotherapy protocol. However, postchemotherapy
surgery led to a major advantage in terms of global survival in very
few cases (9%).
The fact that 85% of our patients underwent primary tumour
surgery is said to be a major recruitment bias, but we would like to
point out that this percentage is the same or lower than that
reported in the majority of studies of metastatic colorectal cancer
(Van Cutsem et al, 2001; Twelves et al, 2001; Schilsky et al, 2002;
Falcone et al, 2002).
As mentioned in the Discussion, low dose intensities of L-HOP
and CPT-11 can be expected when using an alternating
chemotherapy regimen. Nevertheless, the results of the study are
supported by other studies of alternating chemotherapy in patients
with metastatic colorectal cancer, suggesting that prolonged
tumour exposure to a fluoropyrimidine plus full doses of L-HOP Published online 6 July 2004
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